Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Patients on lopinavir/ritonavir-based anti-HIV regimens who simultaneously take medications to reduce gastric acid do not appear to have a reduction in blood concentrations of lopinavir or ritonavir, according to a study reported in the April edition of AIDS Patient Care and STDs. ---------- A Food and Drug Administration advisory panel has recommended accelerated approval of the CCR5 inhibitor maraviroc, to be marketed as Celsentri. Pfizer's maraviroc is the first in this new class of antiretrovirals to be considered for approval for patient use. ---------- Progenics Pharmaceuticals has announced promising data from a Phase Ib clinical trial of CCR5 inhibitor PRO 140. The FDA granted fast-track status for PRO 140 in May, and further clinical trials are scheduled to start this year. ---------- The FDA has approved two tests that help gauge patients' virologic responses to anti-HIV treatment: Abbott Laboratories' RealTime HIV-1 test and Roche's Cobas AmpliPrep/Cobas TagMan HIV-1 Test. ---------- Protease inhibitor darunavir has shown positive results in attacking drug-resistant HIV, according to a study published in the April 7 issue of The Lancet. Darunavir, marketed as Prezista, received accelerated approval last year that required developer Tibotec Pharmaceuticals to continue safety and efficacy testing. Participating in the new study, conducted by the AIDS Healthcare Foundation, were 230 patients who had failed to respond to at least three kinds of anti-HIV meds. All were given a standard drug regimen prescribed by their doctors. In addition, 110 patients received twice-daily doses of darunavir boosted with ritonavir. At 48 weeks 61% of the darunavir group had achieved a 10-fold reduction in viral levels. In the control group about 15% achieved such a reduction. Forty-five percent of the darunavir patients achieved an undetectable viral load, compared to 10% of the control patients. ---------- Ritonavir-boosted atazanavir as maintenance monotherapy was determined to be not as potent as conventional antiretroviral therapy when a study was halted after the threshold number of cases reached virologic failure, according to a report in the April 1 edition of the Journal of Acquired Immune Deficiency Syndromes.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Plus: Featured Video
Latest Stories
The Pride Store: Discover More LGBTQ+ & Ally Brands Tailor Made for Celebrating Your Identity
November 30 2023 3:04 PM
Shop Your Pride: Dive into LGBTQ+ & Ally Brands with The Grand Opening of The Pride Store
November 28 2023 5:32 PM
These Black Queer Podcasts (Featuring Literally Zero Cis White Gay Men) Deserve Your Ears
November 28 2023 11:55 AM
7 Uplifting Films To Celebrate Trans Awareness Week & Where To Stream Them
November 17 2023 10:25 AM
Out's Deal Guide: Grab Your 50% Off Amazon Fire Tablets & More Recommended Deals on Amazon Today!
November 03 2023 3:44 PM
Unlock Massive Savings at 'The Holiday Shop': Amazon's Hottest Deals of the Season Await!
November 02 2023 2:17 PM
Dianne Feinstein’s Commitment to People Living With HIV Won’t Be Forgotten
November 02 2023 1:27 PM
Trending stories
Most Recent
Recommended Stories for You
Plus Editors
Editor
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.